Plain-English translation of NCT06031558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called in people with advanced lung cancer that has a specific genetic change (called a RET fusion). The study will enroll about 120 patients and measure how well the medication works at shrinking tumors, how long people stay without their cancer getting worse, and what side effects occur. This is a Phase III trial, which means the medication has already shown promise in earlier testing.
Many people with this specific type of lung cancer have limited treatment options that work well. This medication is designed to target the exact genetic change driving their cancer, offering hope for a more effective treatment than what is currently available.
You would take the medication by mouth twice daily in 28-day cycles, continuing as long as the cancer does not progress and you do not experience unacceptable side effects. During the study, you will attend regular visits for blood work, imaging scans to check how your cancer is responding, and check-ups with the research team. The study will continue until your cancer progresses, you withdraw from the study, or unacceptable side effects occur.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Shouyao Holdings (Beijing) Co. LTD
Enrollment target
~120 participants
Started
October 2023
Primary completion
April 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.